Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients
-
- Hayashi Norio
- Kansairousai Hospital
-
- Kiyosawa Kendo
- Department of Internal Medicine, Nagano Red Cross Hospital
-
- Tsubouchi Hirohito
- Digestive Disease and Life-style Related Disease, Kagoshima University Graduate school of Medical and Dental Sciences
-
- Okanoue Takeshi
- Saiseikai Suita Hospital
-
- Kumada Hiromitsu
- Toranomon Hospital
Bibliographic Information
- Other Title
-
- B型慢性肝炎患者に対するペグインターフェロンα-2aの有効性及び安全性の検討
- Bガタ マンセイ カンエン カンジャ ニ タイスル ペグインターフェロンa-2a ノ ユウコウセイ オヨビ アンゼンセイ ノ ケントウ
Search this article
Abstract
We investigated the efficacy and safety of PEG-IFN alfa-2a (PEG-IFN) in chronic hepatitis B patients.<br> In this randomized study, HBeAg-positive patients received: PEG-IFN (90 μg/week or 180 μg/week for 24-weeks or 48-weeks) or IFN (6MIU 3×/week for 24-weeks). The primary endpoint was triple response (HBeAg seroconversion, HBV DNA <5 log copies/mL and ALT normalization) at 24-weeks post-treatment.<br> Triple response rates were increased according to the dose and treatment duration in PEG-IFN treatment group. Difference of response rates between PEG-IFN 48-week treatment group and IFN group was 11.3% (95% CI: 0.0-22.6) and confirmed non-inferiority in efficacy and tolerability of PEG-IFN compare to the IFN.<br> In HBeAg-negative patients, PEG-IFN 90 μg/week or 180 μg/week for 48-weeks treatment showed 37.5% or 37.9% of HBV-DNA suppression (<4.3 log copies/mL at 24-weeks post-treatment) respectively.<br> This study confirmed efficacy and safety of PEG-IFN in chronic hepatitis B.<br>
Journal
-
- Kanzo
-
Kanzo 53 (3), 135-146, 2012
The Japan Society of Hepatology
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679771702272
-
- NII Article ID
- 10030547248
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 023522926
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed